세계의 만성 특발성 변비 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Chronic Idiopathic Constipation Treatment Market size is anticipated to grow from USD 3.63 Billion in 2024 to USD 6.77 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.17% during the forecast period of 2026 to 2033.

The chronic idiopathic constipation treatment market is poised for significant growth, driven by the increasing prevalence of gastrointestinal disorders and the rising awareness of available treatment options. Chronic idiopathic constipation (CIC) is a common condition characterized by infrequent bowel movements and difficulty in passing stools, which can significantly impact patients' quality of life. As healthcare providers seek to improve patient outcomes and enhance the management of CIC, the demand for effective therapies, including laxatives, prescription medications, and dietary interventions, is expected to rise, positioning this market for robust expansion.

Moreover, advancements in treatment options for CIC are driving innovation within the market. The development of novel pharmacological agents, such as guanylate cyclase-C agonists and serotonin receptor agonists, has expanded the therapeutic landscape for CIC, offering patients more effective and targeted treatment options. These innovations not only improve bowel function but also address the underlying mechanisms of constipation, enhancing overall patient satisfaction. As research continues to explore new therapies and combination treatments, the chronic idiopathic constipation treatment market is likely to expand further, driven by the promise of improved patient care and quality of life.

Additionally, the growing emphasis on lifestyle modifications and preventive care is shaping the chronic idiopathic constipation treatment landscape. As healthcare providers increasingly recognize the importance of diet, hydration, and physical activity in managing CIC, the demand for educational resources and support programs is likely to increase. This proactive approach not only empowers patients to take control of their condition but also fosters a collaborative relationship between patients and healthcare providers. As the market continues to evolve, the combination of innovative therapies, patient education, and a focus on lifestyle interventions will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Type

• Normal-transit constipation
• Slow-transit constipation
• Others

By Therapy Type

• Pharmacological Therapy
• Non-pharmacological Therapy

By Treatment Type

• Medication
• Surgery

By Drugs

• Serotonin-4 (5-Ht4) Receptor Agonist
• Guanylate Cyclase-C Agonist
• Laxatives
• Stimulants
• Others

By Route of Administration

• Oral
• Injectable

By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others
• COMPANIES PROFILED
• ALLERGAN
• Mallinckrodt plc
• Synergy Pharmaceuticals Inc
• Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
• Takeda Pharmaceutical Company Limited
• Sanofi
• Zydus Cadila
• Boehringer Ingelheim International GmbH
• Shreya Life Sciences Pvt Ltd
• Abbott
• GSK plc
• Troikaa Pharmaceuticals Ltd
• Lupin
• East West Pharma
• Ironwood Pharmaceuticals Inc.
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Therapy Type
  • 3.7.3 Market Attractiveness Analysis By Treatment Type
  • 3.7.4 Market Attractiveness Analysis By Drugs
  • 3.7.5 Market Attractiveness Analysis By Route of Administration
  • 3.7.6 Market Attractiveness Analysis By End-Users
  • 3.7.7 Market Attractiveness Analysis By Distribution Channel
  • 3.7.8 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Normal-transit constipation Historic and Forecast Sales By Regions
• 5.4. Slow-transit constipation Historic and Forecast Sales By Regions
• 5.5. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY THERAPY TYPE

• 6.1. Overview By Therapy Type
• 6.2. Historical and Forecast Data Analysis By Therapy Type
• 6.3. Pharmacological Therapy Historic and Forecast Sales By Regions
• 6.4. Non-pharmacological Therapy Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

• 7.1. Overview By Treatment Type
• 7.2. Historical and Forecast Data Analysis By Treatment Type
• 7.3. Medication Historic and Forecast Sales By Regions
• 7.4. Surgery Historic and Forecast Sales By Regions

8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DRUGS

• 8.1. Overview By Drugs
• 8.2. Historical and Forecast Data Analysis By Drugs
• 8.3. Serotonin-4 (5-Ht4) Receptor Agonist Historic and Forecast Sales By Regions
• 8.4. Guanylate Cyclase-C Agonist Historic and Forecast Sales By Regions
• 8.5. Laxatives Historic and Forecast Sales By Regions
• 8.6. Stimulants Historic and Forecast Sales By Regions
• 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 9.1. Overview By Route of Administration
• 9.2. Historical and Forecast Data Analysis By Route of Administration
• 9.3. Oral Historic and Forecast Sales By Regions
• 9.4. Injectable Historic and Forecast Sales By Regions

10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY END-USERS

• 10.1. Overview By End-Users
• 10.2. Historical and Forecast Data Analysis By End-Users
• 10.3. Hospitals Historic and Forecast Sales By Regions
• 10.4. Homecare Historic and Forecast Sales By Regions
• 10.5. Specialty Clinics Historic and Forecast Sales By Regions
• 10.6. Others Historic and Forecast Sales By Regions

11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 11.1. Overview By Distribution Channel
• 11.2. Historical and Forecast Data Analysis By Distribution Channel
• 11.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 11.4. Retail Pharmacies Historic and Forecast Sales By Regions
• 11.5. Others Historic and Forecast Sales By Regions

12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 12.1. Regional Outlook
• 12.2. Introduction
• 12.3. North America Sales Analysis
  • 12.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 12.3.2 North America By Segment Sales Analysis
  • 12.3.3 North America By Country Sales Analysis
  • 12.3.4 United States Sales Analysis
  • 12.3.5 Canada Sales Analysis
  • 12.3.6 Mexico Sales Analysis
• 12.4. Europe Sales Analysis
  • 12.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 12.4.2 Europe By Segment Sales Analysis
  • 12.4.3 Europe By Country Sales Analysis
  • 12.4.4 United Kingdom Sales Analysis
  • 12.4.5 France Sales Analysis
  • 12.4.6 Germany Sales Analysis
  • 12.4.7 Italy Sales Analysis
  • 12.4.8 Russia Sales Analysis
  • 12.4.9 Rest Of Europe Sales Analysis
• 12.5. Asia Pacific Sales Analysis
  • 12.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 12.5.2 Asia Pacific By Segment Sales Analysis
  • 12.5.3 Asia Pacific By Country Sales Analysis
  • 12.5.4 China Sales Analysis
  • 12.5.5 India Sales Analysis
  • 12.5.6 Japan Sales Analysis
  • 12.5.7 South Korea Sales Analysis
  • 12.5.8 Australia Sales Analysis
  • 12.5.9 South East Asia Sales Analysis
  • 12.5.10 Rest Of Asia Pacific Sales Analysis
• 12.6. Latin America Sales Analysis
  • 12.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 12.6.2 Latin America By Segment Sales Analysis
  • 12.6.3 Latin America By Country Sales Analysis
  • 12.6.4 Brazil Sales Analysis
  • 12.6.5 Argentina Sales Analysis
  • 12.6.6 Peru Sales Analysis
  • 12.6.7 Chile Sales Analysis
  • 12.6.8 Rest of Latin America Sales Analysis
• 12.7. Middle East & Africa Sales Analysis
  • 12.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 12.7.2 Middle East & Africa By Segment Sales Analysis
  • 12.7.3 Middle East & Africa By Country Sales Analysis
  • 12.7.4 Saudi Arabia Sales Analysis
  • 12.7.5 UAE Sales Analysis
  • 12.7.6 Israel Sales Analysis
  • 12.7.7 South Africa Sales Analysis
  • 12.7.8 Rest Of Middle East And Africa Sales Analysis

13. COMPETITIVE LANDSCAPE OF THE CHRONIC IDIOPATHIC CONSTIPATION TREATMENT COMPANIES

• 13.1. Chronic Idiopathic Constipation Treatment Market Competition
• 13.2. Partnership/Collaboration/Agreement
• 13.3. Merger And Acquisitions
• 13.4. New Product Launch
• 13.5. Other Developments

14. COMPANY PROFILES OF CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

• 14.1. Top Companies Market Share Analysis
• 14.2. Market Concentration Rate
• 14.3. ALLERGAN
  • 14.3.1 Company Overview
  • 14.3.2 Company Revenue
  • 14.3.3 Products
  • 14.3.4 Recent Developments
• 14.4. Mallinckrodt Plc
  • 14.4.1 Company Overview
  • 14.4.2 Company Revenue
  • 14.4.3 Products
  • 14.4.4 Recent Developments
• 14.5. Synergy Pharmaceuticals Inc
  • 14.5.1 Company Overview
  • 14.5.2 Company Revenue
  • 14.5.3 Products
  • 14.5.4 Recent Developments
• 14.6. Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • 14.6.1 Company Overview
  • 14.6.2 Company Revenue
  • 14.6.3 Products
  • 14.6.4 Recent Developments
• 14.7. Takeda Pharmaceutical Company Limited
  • 14.7.1 Company Overview
  • 14.7.2 Company Revenue
  • 14.7.3 Products
  • 14.7.4 Recent Developments
• 14.8. Sanofi
  • 14.8.1 Company Overview
  • 14.8.2 Company Revenue
  • 14.8.3 Products
  • 14.8.4 Recent Developments
• 14.9. Zydus Cadila
  • 14.9.1 Company Overview
  • 14.9.2 Company Revenue
  • 14.9.3 Products
  • 14.9.4 Recent Developments
• 14.10. Boehringer Ingelheim International GmbH
  • 14.10.1 Company Overview
  • 14.10.2 Company Revenue
  • 14.10.3 Products
  • 14.10.4 Recent Developments
• 14.11. Shreya Life Sciences Pvt Ltd
  • 14.11.1 Company Overview
  • 14.11.2 Company Revenue
  • 14.11.3 Products
  • 14.11.4 Recent Developments
• 14.12. Abbott
  • 14.12.1 Company Overview
  • 14.12.2 Company Revenue
  • 14.12.3 Products
  • 14.12.4 Recent Developments
• 14.13. GSK Plc
  • 14.13.1 Company Overview
  • 14.13.2 Company Revenue
  • 14.13.3 Products
  • 14.13.4 Recent Developments
• 14.14. Troikaa Pharmaceuticals Ltd
  • 14.14.1 Company Overview
  • 14.14.2 Company Revenue
  • 14.14.3 Products
  • 14.14.4 Recent Developments
• 14.15. Lupin
  • 14.15.1 Company Overview
  • 14.15.2 Company Revenue
  • 14.15.3 Products
  • 14.15.4 Recent Developments
• 14.16. East West Pharma
  • 14.16.1 Company Overview
  • 14.16.2 Company Revenue
  • 14.16.3 Products
  • 14.16.4 Recent Developments
• 14.17. Ironwood Pharmaceuticals Inc
  • 14.17.1 Company Overview
  • 14.17.2 Company Revenue
  • 14.17.3 Products
  • 14.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies